We are live on
!
Find out more
RCP
Remedium Capital Partners Portfolio holdings
AUM
$452M
This Fund
S&P 500
This Quarter
Est. Return
+85.68%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$170M
AUM Growth
–
Cap. Flow
+$143M
Cap. Flow
% of AUM
84.17%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
6
New
6
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ORKA
Oruka Therapeutics
ORKA
|
+$43.3M |
| 2 |
Spyre Therapeutics
SYRE
|
+$38.1M |
| 3 |
Apogee Therapeutics
APGE
|
+$36.8M |
| 4 |
JBIO
Jade Biosciences
JBIO
|
+$18.5M |
| 5 |
CBIO
Crescent Biopharma
CBIO
|
+$4.6M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
WC
FDS
IWMA
BAMG
ECM
BFT
LL
CFA
Remedium Capital Partners's Q4 2025 Portfolio in Review
Q4 2025 is the first quarter with a 13F filing on record for Remedium Capital Partners, which disclosed 6 positions worth $170M. Its ten largest holdings account for 100% of the portfolio.
Its largest position is Oruka Therapeutics: 1,552,414 shares worth $47.1M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- Remedium Capital Partners's largest Q4 2025 buy was Oruka Therapeutics: 1,552,414 shares worth $47.1M.
- Remedium Capital Partners's ten largest holdings make up 100% of its $170M portfolio in Q4 2025.
- Remedium Capital Partners disclosed 6 positions in Q4 2025, its first 13F filing on record.
Based on Remedium Capital Partners's 13F filing for Q4 2025, filed 12 Feb 2026.